[Long-term treatment with sacituzumab govitecan in a patient with brain metastases from triple-negative breast cancer, PD-L1-negative, BRCA1/2 wild-type.].

Authors

Valentina Barbero

Published in

Recenti progressi in medicina. Volume 117. Issue 7-8. Pages e83-e85.

Abstract

We report the clinical case of a 64-year-old female patient who underwent a mastectomy with sentinel lymph node biopsy followed by adjuvant chemotherapy with anthracyclines and taxanes for triple-negative, BRCA wild-type invasive ductal carcinoma. Approximately five years later, she presented with recurrence of the disease in the brain and mediastinal lymph nodes, which was treated with neurosurgical resection of the brain lesion, radiotherapy to the tumour bed and first-line chemotherapy with capecitabine. After 4 months, due to progression of extra-cranial disease and poor gastrointestinal tolerance to oral chemotherapy, the patient was started on second-line chemotherapy with a CMF regimen, achieving a complete metabolic response in the extra-cranial sites. Subsequently, due to clinically symptomatic brain progression in the absence of extracranial recurrence and following multidisciplinary assessment, the patient was started on third-line therapy with sacituzumab govitecan, resulting in symptomatic improvement and a long period of clinical and radiological stability despite dose reduction.

PMID:
42459109
Bibliographic data and abstract were imported from PubMed on 16 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.